1
Shmuel Cabilly, Herbert L Heyneker, William E Holmes, Arthur D Riggs, Ronald B Wetzel: Recombinant immunoglobin preparations. Genentech, March 28, 1989: US04816567 (2766 worldwide citation)

Altered and native immunoglobulins, including constant-variable region chimeras, are prepared in recombinant cell culture. The immunoglobulins contain variable regions which are immunologically capable of binding predetermined antigens. Methods are provided for refolding directly expressed immunoglo ...


2
Winter Gregory Paul: Recombinant antibodies and methods for their production.. Winter Gregory Paul, September 30, 1987: EP0239400-A2 (917 worldwide citation)

An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity using recombinant DNA techniques. The gene coding sequences for producing the altered antibody may be produced ...


3
Ernst B Hunziker: Method and compositions for the treatment and repair of defects or lesions in cartilage. Robert F Shaw, James F Haley Jr, Jane A Massaro, April 27, 1993: US05206023 (358 worldwide citation)

Methods and compositions are provided for the treatment and repair of defects or lesions in the cartilage of humans and other animals. The defect or lesion in the cartilage may be first treated with an enzyme to remove proteoglycans from the defect area. To induce cartilage formation, the defect is ...


4
Ernst B Hunziker: Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone. Robert Francis Shaw, Edward F Mullowney, Jane A Massaro, December 14, 1993: US05270300 (280 worldwide citation)

Methods and compositions are provided for the treatment and repair of defects in the cartilage or bone of humans and other animals as in full-thickness defects in joints. The defect in bone is filled with a matrix having pores large enough to allow cells to populate the matrix and to form blood vess ...


5
Ernst B Hunziker: Methods and compositions for the treatment and repair of defects or lesions in cartilage. Robert F Shaw, James F Haley Jr, Jane A Massaro, November 29, 1994: US05368858 (273 worldwide citation)

Methods and compositions are provided for the treatment and repair of defects or lesions in the cartilage of humans and other animals. The defect or lesion in the cartilage may be first treated with an enzyme to remove proteoglycans from the defect area. To induce cartilage formation, the defect is ...


6
C Richter King, Philip G Kasprzyk, Robert E Bird: Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof. Aronex Pharmaceuticals, C Steven Conley Rose & Tayon P C McDaniel, December 24, 1996: US05587458 (248 worldwide citation)

The present invention relates to novel antibodies, in particular monoclonal and single chain antibodies derived therefrom which specifically bind to erbB-2, as well as diagnostic and therapeutic uses thereof. The present invention also relates to a combination of at least two erbB-2 specific antibod ...


7
Danute E Nitecki: Preparation of an activated polymer ester for protein conjugation. Cetus Oncology Corporation, Grant D Green, Kenneth M Goldman, Philip L McGarrigle Jr, January 25, 1994: US05281698 (226 worldwide citation)

The present invention is a process for preparing an activated ester of polyethylene glycol or a polyoxyethylated polyol. After the activated ester is prepared, it can be reacted with a protein to form a polymer/protein conjugate. Conjugation with a polymer can reduce the protein's immunogenicity, in ...


8
Shui on Leung, Hans Hansen: Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells. Immunomedics, Foley & Lardner, August 4, 1998: US05789554 (189 worldwide citation)

A chimeric LL2 monoclonal antibody is described in which the complementarity determining regions (CDRs) of the light and heavy chains of the murine LL2 anti-B-lymphoma, anti-leukemia cell monoclonal antibody has been recombinantly joined to the human kappa and IgG.sub.1 constant region domains, resp ...


9
Darcy V Spicer, Malcolm C Pike: Contraceptive methods and formulations for use therein. University of Southern California, Robbins Dalgarn Berliner & Carson, May 18, 1993: US05211952 (140 worldwide citation)

Contraceptive devices which are effective for extended periods of time are described, in the form of means for releasing an effective amount of a gonadotropin hormone releasing hormone composition and means for releasing an effective amount of an estrogenic hormone over a first period of time, and m ...


10
Marshall R Urist: Bone morphogenetic protein composition. The Regents of the University of California, Kenyon & Kenyon, August 2, 1988: US04761471 (140 worldwide citation)

BMP compositions including the human factor and bovine factor thereof, the process of isolating BMP compositions and factors, and the use of such factors and compositions to induce bone formation in animals.